Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
April 2019
-
Media ReleaseAveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, ColoradoFacility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
-
Media ReleaseNovartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM TreAcquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
March 2019
-
Key ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseMayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
What goes wrong with the window to the soul in glaucoma?
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Key ReleaseNovartis plans for Alcon spin-off on April 9, 2019Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
-
Experimental gene therapy discovered in-house enters clinical testing
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
-
In The NewsIt's Time to "Pivot Towards Transformational Innovation"In this interview with Susie Gharib from Fortune, Vas Narasimhan, CEO of Novartis, shares his perspective on changing the culture within Novartis.
-
Visualizing immuno-oncology research
Learn how Novartis researchers are working to outsmart tumors.
-
Media ReleaseAlcon Announces Acquisition of PowerVision, Inc.Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
-
Media ReleaseNovartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathyStudy is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019…
-
Featured NewsGlobal Equal Parental Leave Policy for all Novartis parents
Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.
-
Key ReleaseNovartis announces change in Sandoz leadershipRichard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
Pagination
- ‹ Previous page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- …
- 152
- › Next page